Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 225Lymphoma, Large B-Cell, Diffuse 160Small Cell Lung Carcinoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Lymphoma, Non-Hodgkin 139Leukemia 135Leukemia, Myeloid, Acute 117Hodgkin Disease 106Lung Neoplasms 99Burkitt Lymphoma 99Lymphoma, Follicular 85Lymphoma, Mantle-Cell 76Lymphoma, Large-Cell, Immunoblastic 68Carcinoma, Non-Small-Cell Lung 61Neuroblastoma 60Leukemia, Lymphocytic, Chronic, B-Cell 56Recurrence 53Multiple Myeloma 52Lymphoma, B-Cell, Marginal Zone 43Congenital Abnormalities 43Sarcoma 39Central Nervous System Neoplasms 39Myelodysplastic Syndromes 35Brain Neoplasms 34Ovarian Neoplasms 32Leukemia, Myelomonocytic, Acute 32Lymphoma, B-Cell 31Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 31Testicular Neoplasms 30

Interventions

Gemcitabine 25Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3Immunoglobulin G 3Disulfides 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × Etoposide × Clear all
NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡